KRAS and non-small cell lung carcinoma: In this context, KRAS G12C inhibitors are being evaluated as a first-line therapeutic option in patients with NSCLC harboring STK11 and KRAS G12C co-mutations (KRYSTAL-1 and CodeBreaK 201).